FindTrial
Sign In

The effects of Transjugular Intrahepatic Portosystemic Shunt placement on von Willebrand factor levels in plasma of patients with cirrhosis and portal hypertension.

The effects of Transjugular Intrahepatic Portosystemic Shunt placement on von Willebrand factor levels in plasma of patients with cirrhosis and portal hypertension. - VWF-TIPS study

Status
Unknown
Phases
Unknown
Study type
Observational
Source
NL-OMON
Registry ID
NL-OMON38711
Enrollment
16
Registered
2013-05-07
Start date
Unknown
Completion date
Unknown
Last updated
2024-04-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

increased pressure in the liver portal hypertension

Interventions

None listed

Sponsors

Universitair Medisch Centrum Groningen
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: - Patient with cirrhosis undergoing TIPS placement - >=18 years of age - Signed informed consent

Exclusion criteria

Exclusion criteria: Patients with hemophilia A or von Willebrands disease

Design outcomes

Primary

MeasureTime frame
The level of von Willebrand factor prior to, directly after, one week after, and one month after placement of a transjugular intrahepatic portosystemic shunt.—

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)